CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for EIR Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

EIR Biopharma Inc
92 Natoma Street, Suite 200
Phone: (415) 495-7111p:415 495-7111 SAN FRANCISCO, CA  94105  United States
Business Summary
EIR Biopharma, Inc. is an early-stage biopharmaceutical company focused on developing therapeutics for the treatment of eye disease. The Company’s advancing EIR-0205 and EIR-1003 into IND-enabling toxicological studies in animals in accordance with Good Laboratory Practice (GLP) guidelines, and into manufacturing and drug product formulation in accordance with Good Manufacturing Practice (GMP) guidelines in anticipation of commencing Phase I clinical trials. EIR-0205 is a small-molecule drug, licensed by Cornell University, and it intends to be developed for treatment of the atrophic dry form of age-related macular degeneration (dry AMD). EIR-0205 is a functionalized cyclodextrin designed to extract lipofuscin, a waste product that accumulates in the retinal epithelium causing degeneration of the retina leading to dry AMD. EIR-1003 is a peptidomimetic drug candidate licensed from the University of Miami, designed to mimic ephrin ligands.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Anthony J.Cataldo 75 2/1/2022 2/1/2022
President, Chief Financial Officer, Chief Science Officer, Treasurer, Secretary, Director MartinSchroeder 72 2/1/2022 2/1/2022

General Information
Outstanding Shares: 3,750,000 (As of 9/30/2025)
Federal Tax Id: 880595900


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 1, 2026